AstraZeneca Reports ODAC's Review Of Imfinzi - Quick Facts

(RTTNews) - AstraZeneca (AZN.L, AZN) said the Food and Drug Administration's Oncologic Drugs Advisory Committee acknowledged that Imfinzi met the primary endpoint of event-free survival in the treatment of resectable non-small cell lung cancer based on the AEGEAN Phase III trial https://www.nasdaq.com/articles/astrazeneca-reports-odacs-review-imfinzi-quick-facts